• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: AAN 2013

Disease activity-free rates at 1 and 2 years

March 23, 2013  

Second-line switching: three reports

March 23, 2013  

CCSVI: has the balloon burst?

March 23, 2013  

BG-12: two analyses of safety results

March 22, 2013  

Natalizumab update: anti-JCV Ab testing and PML risk

March 22, 2013  

Brain atrophy reduced with fingolimod

March 22, 2013  

Pregnancies may slow disability progression

March 21, 2013  

Update on treatment trials: teriflunomide, daclizumab and CombiRx

March 21, 2013  

Effect of NaCl on pathogenic Th17 cells

March 21, 2013  

Browse by Topic

MS (332)
AD (81)
PD (77)
COVID-19 (58)
PREVIOUS CONGRESSES (37)
DEPRESSION (36)
MIGRAINE (26)
SCHIZOPHRENIA (25)
STROKE (22)
EPILEPSY (21)
ECTRIMS 2015 (13)
Library (13)
AAN 2015 (11)
ECTRIMS 2019 (10)
ECTRIMS 2021 (10)
ECTRIMS 2014 (10)
DEMENTIA (10)
ECTRIMS 2018 (9)
MS SEQUENCING (9)
ECTRIMS 2013 (9)
AAN 2014 (9)
AAN 2013 (9)
CLINICAL CASES IN MS (8)
PSYCHIATRY (8)
AAN 2019 (7)
ACTRIMS-ECTRIMS 2020 (7)
ECTRIMS 2017 (6)
CHARCOT 2013 (6)
AAN 2021 (6)
ECTRIMS 2022 (6)
ECTRIMS 2016 (5)
CCSVI (5)
BIPOLAR (5)
ANXIETY (5)
AAN 2022 (5)
NeuroSound (4)
BPD (4)
EAN 2015 (4)
AAN 2020 (3)
PAIN (3)
EAN 2022 (3)
AAN 2017 (3)
ENS 2013 (3)
SPECIAL REPORT (2)
EAN 2020 (2)
NEW DRUGS (2)
SLEEP (2)
APA 2014 (2)
AAN 2018 (2)
hATTR (1)
LUMBAR PUNCTURE (1)
LGS (1)
GUIDELINES (1)
ACTRIMS 2022 (1)
SEIZURE (1)
ALS (1)
EAN 2021 (1)
TSC (1)
APA 2016 (1)
INSOMNIA (1)
AAN 2016 (1)
Dravet syndrome (1)
CIDP (1)
CONCUSSION (1)
ADDICTION (1)
WEST NILE (1)
EAN 2019 (1)
EAN 2016 (0)
ECTRIMS 2020 (0)
View all Topics

Popular Posts

  • CLINICAL CASES IN MS – AN OLDER PATIENT WITH STABLE DISEASE posted on January 10, 2023
  • The end of MS phenotypes? posted on January 26, 2023
  • MS Awards 2022 – Oddities and Observations posted on December 9, 2022
Copyright 2023 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions